Effect of Zofa (Nepeta bracteata Benth.) Product on Chronic Obstructive Pulmonary Disease
Phase 2
- Conditions
- Chronic Obstractive Pulmonary Disease.Other specified chronic obstructive pulmonary disease
- Registration Number
- IRCT2015121925598N1
- Lead Sponsor
- Vice chancellor for research, Shahed University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Including criteria:
Mild to Moderate Chronic Obstructive Pulmonary Disease; Age 18 and more; no allergy to the Lamiaceae family; no lactation or pregnancy; not having Diabetes and history of epilepsy and seizure
Excluding criteria: Exacerbation period
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of quality of life of patients. Timepoint: The time of study inclusion and two and four weeks later. Method of measurement: COPD Assessment Test (CAT) Questionnair.;Chenge of FEV1 (Forced Expiratory volume in 1 second). Timepoint: Before treatment and four weeks after treatment. Method of measurement: Spirometry super Spiro, Micro medical company, England.
- Secondary Outcome Measures
Name Time Method